Biotechnology
YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023
GAITHERSBURG, Md., May 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
DISCOVERY LIFE SCIENCES JOINS AKOYA BIOSCIENCES' GLOBAL SERVICE PROVIDER NETWORK TO ACCELERATE IMMUNO-ONCOLOGY RESEARCH
HUNTSVILLE, Ala., May 18, 2023 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, announced today that it has officially qualified as one of Akoya Biosciences' global service providers. The qualification process evaluated Discovery's proficiency in ...
Top-quality medical grade TPUs enabled by smart factory: ICP DAS - BMP to exhibit at Medtec China 2023
HSINCHU, May 18, 2023 /PRNewswire/ -- Smart manufacturing & stringent process control enhance TPU quality. ICP DAS - BMP (Biomedical Polymers), aTaiwan-based supplier of medical-grade TPU (thermoplastic polyurethane), acts as a front-runner who deploys IIoT systems in a smart factory to maintain ...
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswi...
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
* ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncologyand Antengene's third drug candidate to enter clinical studies in the U.S. * The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacolo...
Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan
HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, May 17, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the"Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeuti...
Inclusion of Recbio In the MSCI China Small Cap Index
TAIZHOU, China, May 17, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, MSCI announced the results of the semi-annual review of the MSCI Global Small Cap Indexes onMay 12, 2023, and the Company has ...
Antengene Announces NDA Submission for XPOVIO® in Indonesia
SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density
SUZHOU, China, May 17, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces encouraging phase I cl...
Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings
ROCKVILLE, Md. and SUZHOU, China, May 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
* Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. * Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA dama...
Boan Biotech's BA1202 Approved for Clinical Trial
-The First Novel CEA/CD3 Bispecific Antibody in China- YANTAI, China, May 16, 2023 /PRNewswire/ -- Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation ofChina's National Medical Products A...
DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president
- Reorganizing the global sales networks and enhancing its capabilities to get global approvals for new drug - Accelerating value of the new drug pipelines SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointedYong Gu Lee as the new CEO and ...
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan
GAITHERSBURG, Md., May 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious d...
Cambrex Completes Expansion of Snapdragon Chemistry Facility in Waltham, Massachusetts
EAST RUTHERFORD, N.J., May 16, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that Snapdragon Chemistry has completed the se...
LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis
HANGZHOU, China, May 16, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that the Phase II clinical trial of LNK01001 in the treatment of rheumatoid arthritis (RA) showed statistically signifi...
Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech's Dulaglutide Injection BA5101 in China
YANTAI, China, May 15, 2023 /PRNewswire/ -- Boan Biotech today announced the completion of patient enrollment for the Phase III clinical trial (a comparative clinical study of efficacy and safety) of the company's Dulaglutide Injection (BA5101) inChina. BA5101 is a biosimilar of Trulicity®, used...
Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma
* Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001, a potentially best-in-class anti-HER3 mAb, in combination with cetuximab, an anti-EGFR mAb, in sqNSCLC * HMBD-001 used as monotherapy and in combination with cetuximab has been ...
MGI Empowers the Completion of Nearly 60,000 Samples for The Million Microbiome of Humans Project
SHENZHEN, China, May 15, 2023 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, recently shared that a total of nearly 60,000 samples have been sequenced among 21 institutes and over 10 participating nations throughoutEurope, ...
Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis
SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Keymed", HKEX: 02162), today announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for Glomerulonephritis (also referred as severe kidney diseases). The collaborat...
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 320 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07